Common Stock, par value $0.01 per share
- Symbol
- EMBC
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Embecta Corp.
EMBCNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On February 5, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended December 31, 2025. The Press Release is furnished as Exhibit 99.1 to this report.
Press release in this filing
Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results →Company context
embecta is a global diabetes care company that is leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
Current securities
Historical securities (1)
Registered securities in this filing
EMBECTA CORP. · 8-K · Filed 2026-02-05
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02.
Results of Operations and Financial Condition.
On February 5, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended December 31, 2025. The Press Release is furnished as Exhibit 99.1 to this report.
Filed exhibits (1)
FOR IMMEDIATE RELEASE Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results PARSIPPANY, N.J., Feb 5, 2026 (GLOBE NEWSWIRE) - Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three month period ended December 31, 2025. "During the first quarter our results were largely consistent with our expectations," said Devdatt (Dev) Kurdikar, President and Chief Executive Officer of embecta. Mr. Kurdikar added, "As we look ahead, we remain focused on pursuing initiatives that will transform the company into a broad-based medical supplies company which serves chronic care patients and drug delivery partners. This includes maintaining our global leadership position in core injection products, expanding our product portfolio, and creating additional financial flexibility through ongoing debt reduction. Given our performance during the first quarter, coupled with our outlook for the remainder of the year, we are maintaining our previously provided guidance for key financial reporting metrics." First Quarter Fiscal Year 2026 Financial Highlights: • Reported revenues of $261.2 million, down 0.3% on a…
Open exhibit ↗